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Abstract It has been shown that the molecular mechanism by
which cytokines and glucocorticoids mutually antagonize their
functions involves a mutual glucocorticoid receptor (GR)/nuclear
factor-UB (NF-UB) transrepression. Here we report a role for the
nuclear receptor coactivator RAC3, in modulating NF-UB
transactivation. We found that RAC3 functions as a coactivator
by binding to the active form of NF-UB and that overexpression
of RAC3 restores GR-dependent transcription neglecting GR/
NF-UB transrepression. The competition between GR and NF-
UB for binding to RAC3 may represent a general mechanism by
which both transcription factors mutually antagonize their
activity. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Nuclear factor-U-B (NF-UB) is a ubiquitous mammalian
transcription factor that is activated in response to a wide
variety of extracellular stimuli including endotoxins and in-
£ammatory cytokines such as interleukin-1 (IL-1) or tumor
necrosis factor-K (TNF-K) [1^3]. In addition to its pivotal
role in immune response and in£ammation, NF-UB regulates
the expression of genes that control cell cycle [4,5] and cell
viability [6^10]. NF-UB consists of dimers of proteins contain-
ing the Rel dimerization domain, the p50/p65 (Rel-A) hetero-
complex being the best characterized at present. Inactive NF-
UB is trapped in the cytoplasm by association with IUB inhib-
itor proteins. Phosphorylation of IUB by speci¢c kinases acti-
vated by extracellular signals mark IUB for degradation,
thereby allowing activation of the NF-UB complex, which
subsequently translocates to the nucleus to modulate target
gene expression by binding, in a sequence-speci¢c fashion,
to UB promoter elements [1^3].
In£ammatory cytokines acting at the hypothalamic^pitui-
tary^adrenal axis induce the synthesis of glucocorticoids,
which function as major immunosuppressive agents in mam-
mals [11^15]. Generally, glucocorticoids control gene expres-
sion by binding to and thereby activating the glucocorticoid
receptor (GR), which subsequently translocates to the nucleus
and binds to the glucocorticoid response element (GRE) at
target gene promoters [16].
The molecular mechanism by which glucocorticoids exert
immunosuppression has been believed to involve: (a) interfer-
ence at the UB-responsive promoter due to a physical inter-
action between GR and Rel-A and (b) the induction of IUB
expression which prevents NF-UB activation [17^19].
In the past few years it has become evident that controlled
transcription involves the participation of coactivators, a
growing family of di¡erent molecules with intrinsic transacti-
vation domains and various additional enzymatic functions.
Some ‘general’ coactivators are: CBP (cyclic AMP response
element binding protein (CREB)-binding protein) or its ho-
molog p300, and molecules of the p160 coactivator family,
which consists of SRC-1 (steroid receptor coactivator-1),
TIF-2 (transcriptional intermediate factor-2), and RAC3
(mouse SRC-3). They participate in transcriptional regulation
by interacting with a great number of nuclear receptors and
various transcription factors [20^23].
SRC-1 has been shown to interact with NF-UB by binding
to p50 thereby enhancing UB-dependent transcriptional activ-
ity [24]. Similarly, CBP binds to p65 and enhances NF-UB-
mediated transactivation in a protein kinase A (PKA)-depen-
dent manner [25]. In addition, Sheppard et al. demonstrated
that NF-UB recruits a coactivator complex that has striking
similarities to that recruited by nuclear receptors [26]. Over-
expression of CBP/p300 or SRC-1 was shown to relieve mu-
tual GR/NF-UB transrepression, indicating a possible compe-
tition for limiting amounts of coactivators for controlled UB
transactivation [27]. In contrast to these observations, McKay
and Cidlowski have recently reported that the mechanism of
transrepression between both transcription factors is not so
simple and they propose an integrative model, where CBP
plays a critical role stabilizing the GR/NF-UB interaction
and enhancing their antagonism [28]. Moreover, there is addi-
tional evidence supporting the hypothesis that glucocorticoids
repress NF-UB activity by disturbing the Rel-A interaction
with the basal transcription machinery, irrespective of the
levels of expression of coactivators in the cell [29].
Although there is a growing source of evidence showing the
complexity in the cross-talk between NF-UB and GR, it is not
known whether other members of the p160 family play similar
roles in response to physiological stimuli to activate NF-UB.
In particular, RAC3, a gene overexpressed in primary breast
tumor tissues [30], has not been reported to be involved in the
regulation of UB transcription to date. Therefore, we decided
to investigate the role of RAC3 on TNF-K-induced NF-UB
transcriptional activity and its e¡ect on the mutual GR/NF-
UB transrepression. We found that RAC-3 is an NF-UB co-
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activator, and that the overexpression of RAC3 overcomes
the mutual GR/NF-UB transrepression.
2. Materials and methods
2.1. Cells and reagents
Human cervix carcinoma HeLa cells were grown in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) (Gibco Laboratories, Grand Is-
land, NY, USA) supplemented with 10% charcoal-stripped steroid-
free fetal calf serum (Gibco, Paisley, UK), penicillin (100 U/ml) and
streptomycin (100 mg/ml). Cells were maintained at 37‡C in a humidi-
¢ed atmosphere with 5% CO2. Unless stated, reagents were obtained
from Sigma (St. Louis, MO, USA) or Pharmacia (Uppsala, Sweden).
2.2. Expression vectors and reporter plasmids
UB-Luc reporter plasmid was kindly provided by Dr. Omar Coso,
Universidad de Buenos Aires, Argentina; ssIUB expression vector
carrying mutated Ser 32 and Ser 36 to prevent phosphorylation and
proteolysis of IUB was generously provided by Dr. G. Cadwell and
Dr. M. Karin, University of California, La Jolla, CA, USA; and
human Rel-A expression vector was provided by Dr. J. DiDonato,
Cleveland Clinic. GRE reporter plasmid (MMTV-Luc) and expression
vectors for coactivators pCR3.1-SRC-1 and pVL-CBP were previ-
ously described [31]; pSG5-TIF-2 was kindly provided by Dr. H.
Gronemeyer [32] and pCMX-RAC3 was a gift from Dr. R. Evans,
The Salk Institute, San Diego, USA.
2.3. Transfections assays
Cells were cultured in six-well plates at a density of 3U105 cells/well
in DMEM without serum or antibiotics and transiently transfected
with totally 3^4 Wg of DNA (including 0.5 Wg of reporter and 0.5 Wg
of constitutive RSV-L-gal control vector) using lipofectamine (Gibco
BRL). After 5 h transfection medium was replaced by DMEM 10%
charcoal-stripped serum. Cells were stimulated with human TNF-K
(Calbiochem) at a concentration of 10 or 20 ng/ml and dexametha-
sone (DEX) at a concentration of 50 or 500 nM, as indicated, and
cultured for 24 h prior harvesting.
Cellular extracts for Luc and L-gal assays were prepared, and assays
were performed using the appropriate substrates following the man-
ufacturer’s protocols (Promega).
2.4. Immunoprecipitations and Western blots
Co-immunoprecipitations were performed as previously described
[31]. Brie£y, transfected HeLa cells overexpressing HA-tagged
RAC3 or transfected with empty control vector were stimulated
with 10 ng/ml of TNF-K for 45 min and then lyzed in a bu¡er
(50 mM Tris, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.2% Nonidet
P-40) containing 1 mM dithiothreitol and the protease inhibitors
10 Wg/ml leupeptin, 10 Wg/ml aprotinin, 1 Wg/ml pepstatin A and
1 mM phenylmethylsulfonyl £uoride. Supernatants of lysates were
incubated overnight at 4‡C with HA antibody (Santa Cruz Biotech-
nology, CA, USA) and immunoprecipitated for 2 h at 4‡C with Gam-
maBind G Sepharose (Pharmacia Biotech, USA). After six washes,
Sepharose-bound immunocomplexes were separated on 8% SDS^
PAGE and electro-transferred to nitrocellulose membranes. Mem-
branes were blocked for non-speci¢c binding with a solution contain-
ing 5% bovine serum albumin (IgG-free) and 0.05% Tween-20 and
incubated for 60 min at room temperature in phosphate-bu¡ered sa-
line and 0.5 Wg/ml Rel-A antibody (Santa Cruz Biotechnology, CA,
USA). Subsequently, membranes were incubated for 45 min with
horseradish peroxidase-conjugated secondary antibody, and the pro-
teins visualized by autoradiography using the chemiluminescence lu-
minol reagent (Santa Cruz Biotechnology, CA, USA).
3. Results and discussion
3.1. E¡ect of RAC3 on NF-UB transcriptional activity induced
by TNF-K
In order to determine the role of RAC3 on NF-UB tran-
scriptional activity, we transiently transfected HeLa cells with
di¡erent amounts of RAC3 expression vector along with UB-
Luc reporter construct and stimulated NF-UB transactivation
by treating the cells with TNF-K. As shown in Fig. 1, over-
expression of RAC3 signi¢cantly enhanced TNF-K-induced
basal NF-UB transcriptional activity in a dose-dependent
manner. Similar results were obtained with cells that were
transiently overexpressing Rel-A in order to emulate constitu-
tive NF-UB transactivation (data not shown). These results
demonstrate that RAC3 enhances NF-UB-transcriptional ac-
tivity in response to physiological stimuli such as TNF-K.
Due to its ability to interact with other coactivators, CBP
has been identi¢ed as a crucial component for nuclear recep-
tor transactivation [20^23]. In addition, it was previously
shown that CBP binds physically to the p50 component of
NF-UB [25]. In agreement with these observations, we found
that overexpression of CBP also enhanced NF-UB transcrip-
tion, albeit to a lesser extent than the coactivation by RAC3.
The overexpression of both coactivators resulted in an addi-
tive transcriptional coactivation (Fig. 1B).
Previous studies have shown that cells transiently trans-
fected with Rel-A require TIF-2 or SRC-1 for UB-dependent
transcription [26]. Accordingly, we report here that both co-
activators enhanced NF-UB transcriptional activity in HeLa
cells stimulated by TNF-K in a dose-dependent manner (Fig.
2). Taken together, these results show that, despite some func-
tional divergence among the p160 members [23], all tested
coactivators were able to enhance UB-mediated transcription
upon a physiological stimulus in cell culture, indicating that
coactivators may play an important role in controlling NF-UB
target gene expression.
Fig. 1. Role of RAC3 on UB-mediated transcription. HeLa cells
were transfected with 500 ng UB-Luc reporter plasmid, 500 ng of
RSV-L-GAL and 2 Wg of either pCMX empty vector or pCMX-
RAC3 (A) or 500 ng pVL-CBP (B) and the cells stimulated with
TNF-K as indicated. Bars represent the average of relative light
units (RLU) of assay. Similar results were obtained in three inde-
pendent experiments, S.D. was less than 10%.
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3.2. RAC3 coactivator interacts with the Rel-A heterocomplex
and requires activated NF-UB for UB transactivation
In order to elaborate on the preceding ¢ndings, we wanted
to know if RAC3 is capable of physically interacting with the
active NF-UB complex. We therefore performed co-immuno-
precipitation experiments with HeLa cells. In these experi-
ments, the cells were stimulated with TNF-K in order to en-
sure high levels of active NF-UB complex, for putative
interaction with the coactivator. As shown in Fig. 3A, Rel-
A protein was readily detected in the RAC3 immunoprecipi-
tate. These data suggest that RAC3 and Rel-A may be part of
the same protein complex by direct binding or through an
indirect association mediated by other proteins.
In order to determine if the e¡ect of RAC3 on NF-UB-
mediated transcription is speci¢cally mediated by the acti-
vated form of NF-UB, we transiently transfected HeLa cells
with UB-Luc reporter along with vectors expressing RAC-3
and the mutated inhibitor of NF-UB (ssIUB). This mutant is
not susceptible to phosphorylation and hence, does not under-
go proteolysis upon TNF-K stimulation and, for that reason,
constitutively suppresses NF-UB activation. As shown in Fig.
3B, overexpression of ssIUB entirely inhibited TNF-K-induced
NF-UB transactivation. In addition, abundant RAC3 was un-
Fig. 2. Role of coactivators on UB-mediated transcription. Cells
were transfected with 500 ng of UB-Luc reporter plasmid and 500
ng of RSV-L-GAL along with the indicated amounts of coactivators
pCR3.1-SRC-1 or pSG5-TIF-2. The total amount of DNA was 3 Wg.
Diagram bars represent the average of triplicate values. Similar re-
sults were obtained in three independent experiments. S.D. was less
than 10%.
Fig. 3. A: Western analysis for Rel-A in RAC3 immunoprecipitates.
Anti-HA immunoprecipitates from cells transfected with either
empty vector (lane 1) or pCMX-HA-tagged RAC3 (lane 2) and
stimulated with 10 ng/ml of TNF-K for 45 min are shown. B: E¡ect
of RAC3 on UB-mediated transcription in the absence of active NF-
UB. Cells were transfected with 500 ng of UB-Luc reporter plasmid,
500 ng of RSV-L-GAL, 0.5 Wg of pCMX-RAC3 or empty vector,
and 1 Wg of ssIUB expression vector and stimulated as indicated. Di-
agram bars represent the RLU of assay. Similar results were ob-
tained in three independent experiments. A similar e¡ect of ssIUB
was also observed in cells transfected with 1 Wg of pCMX-RAC-3
and 500 ng of ssIUB.
Fig. 4. Role of RAC3 in the mutual GR/NF-UB transrepression. A:
Cells were transfected with 500 ng of the GRE reporter MMTV-
Luc, 500 ng of RSV-L-GAL and 1 Wg of pCMX-RAC3 or the
empty vector and stimulated with 50 nM of DEX and 10 ng/ml of
TNF-K, as indicated. Diagram bars are the average þ S.D. of three
independent experiments. B: Cells were transfected with 500 ng of
the GRE reporter, 500 ng of RSV-L-GAL, increasing doses of Rel-
A expression vector (200 ng, 500 ng, 1 Wg) and RAC3 expression
vector and stimulated with 500 nM of DEX as indicated. Diagram
bars represent the RLU of assay. C: Cells were transfected with 500
ng of UB-Luc reporter, 500 ng of RSV-L-GAL, 1 Wg of pCMX-
RAC3 or the empty vector, 1 Wg of ssIUB expression vector and
stimulated with TNF-K and DEX, as indicated. Diagram bars repre-
sent the average þ S.D. of three independent experiments.
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able to overcome this suppression. These results, together with
the ability of the coactivator to enhance UB promoter activity
in stimulated cells, demonstrate that the e¡ect of RAC3 on
UB-dependent transcriptional activity is absolutely dependent
on the presence of an active form of NF-UB.
3.3. RAC3 coactivator rescues both GRE- and UB-dependent
transcription from the mutual inhibitory e¡ect between
TNF-K-induced NF-UB and GR
Although very low doses of TNF-K, such as 0.02 ng/ml,
may enhance the GR transactivation [33], this cytokine and
glucocorticoid antagonize each others e¡ect in the NF-UB/
GR-pathways, [17^19]. A physical interaction between GR
and NF-UB may partially account for the mutual transrepres-
sion, however, the induction of IUB expression by GR is not
su⁄cient to explain Rel-A-mediated downregulation of GR
transactivation.
In order to determine if competition for limiting quantities
of endogenous RAC3 might be a possible mechanism under-
lying the mutual GR/NF-UB antagonism, we analyzed GRE
as well as UB-mediated transcription under RAC3-saturated
conditions. These experiments were performed with or with-
out the addition of DEX and/or TNF-K.
First, we examined the role of RAC-3 on NF-UB transre-
pression of GRE-dependent transcription. We co-transfected
HeLa cells with GRE reporter plasmid along with ‘empty’
control plasmid or RAC3 expression vector and analyzed
GR transcriptional activity of cells treated with DEX, TNF-
K or a combination of both.
As shown in Fig. 4A, co-treatment with TNF-K (10 ng/ml)
inhibited GRE-mediated transactivation stimulated with 50
nM DEX. The presence of abundant RAC3 reversed squelch-
ing for the coactivator and resulted in a signi¢cantly reduced
TNF-K-induced transrepression (Fig. 4A). Similar results were
obtained with non-stimulated cells that were transfected with
an expression vector for Rel-A protein in a dose-dependent
manner (Fig. 4B). Increasing amounts of RAC3 reversed the
e¡ect for the maximal dose of Rel-A applied in the experi-
ment.
We wanted to determine if RAC3 is also capable of over-
coming the GR inhibition of TNF-K-stimulated NF-UB tran-
scription and for that purpose we employed a similar ap-
proach. Fig. 4C shows that overexpression of RAC3 again,
was su⁄cient to overcome NF-UB/GR transrepression. How-
ever, in this experiment, much higher levels of glucocorticoids
(500 nM of DEX) were required to lower UB-mediated trans-
activation (42 þ 10%) while in the previous experiment, the
addition of DEX at 50 nM was su⁄cient to signi¢cantly in-
duce GRE-transcriptional activation (Fig. 4A).
Treatment with DEX alone had no e¡ect on UB-transcrip-
tional activity, which was not a¡ected by the presence of
abundant RAC3 (Fig. 4C). In addition, co-transfection with
ssIUB expression vector reduced NF-UB transcriptional activ-
ity almost to basal levels even under conditions of Rac-3 over-
expression. Taken together, these results indicate that the re-
storation of the DEX e¡ect by RAC3 requires the active form
of NF-UB and is not due to the binding of RAC3 to another
transcription factor.
Since overexpression of RAC3 does not overcome the in-
hibitory e¡ect of ssIUB, and RAC3 speci¢cally enhances the
transcriptional activity of activated, inhibitor-depleted NF-
UB; we believe in the existence of an additional mechanism
responsible for the mutual antagonism of glucocorticoids and
cytokines on UB/GRE-transcription. Such a mechanism is sen-
sitive to the cellular levels of RAC3 and is not constrained by
the activation of IUB proteolysis. Under physiological condi-
tions where both GR and NF-UB pathways are in need of
coactivators, the model supports the action of RAC3 as a
limiting cofactor. Thus, the competitive squelching of RAC3
by both activated pathways may contribute to the mutual
transrepression.
According to other publications, there is strong evidence
that the induction of IUB by glucocorticoids is not a general
molecular mechanism that may explain the NF-UB transre-
pression [28,29]. Moreover, it was previously shown that in
U937 cells, glucocorticoids do not prevent neither the nuclear
localization of NF-UB nor its binding to DNA, but rather
change the complex into a transcriptionally inert form [34].
While some authors have suggested that coactivators may
constitute a limiting factor for transcriptional activity, others
have shown that one coactivator may stabilize the transcrip-
tionally inactive complex GR/NF-UB [28].
In view of these evidences, it becomes clear that the mutual
transrepression between GR and NF-UB involves more than
one mechanism which probably depends of the cellular sce-
nario, promoter type, coactivator levels and physiological
context.
Our results support the idea that the competition for coac-
tivators is one of the molecular mechanisms that explain GR/
NF-UB mutual transrepression, where RAC3, being a limiting
factor, plays a critical role as an NF-UB and GR coactivator.
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